Schiffmann R - Search Results

1

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT; Fabry Outcome Survey investigators. Mehta A, et al. Among authors: schiffmann r. Lancet. 2009 Dec 12;374(9706):1986-96. doi: 10.1016/S0140-6736(09)61493-8. Lancet. 2009. PMID: 19959221

2

Fabry's disease--an important risk factor for stroke.

Schiffmann R, Ries M. Schiffmann R, et al. Lancet. 2005 Nov 19;366(9499):1754-6. doi: 10.1016/S0140-6736(05)67636-2. Lancet. 2005. PMID: 16298202 No abstract available.

3

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R. Ries M, et al. Among authors: schiffmann r. Pediatrics. 2006 Sep;118(3):924-32. doi: 10.1542/peds.2005-2895. Pediatrics. 2006. PMID: 16950982 Clinical Trial.

4

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R. Ries M, et al. Among authors: schiffmann r. J Clin Pharmacol. 2007 Oct;47(10):1222-30. doi: 10.1177/0091270007305299. Epub 2007 Aug 13. J Clin Pharmacol. 2007. PMID: 17698592 Clinical Trial.

5

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.

Clarke JT, West ML, Bultas J, Schiffmann R. Clarke JT, et al. Among authors: schiffmann r. Genet Med. 2007 Aug;9(8):504-9. doi: 10.1097/GIM.0b013e318133fb1b. Genet Med. 2007. PMID: 17700388 Free article. Clinical Trial.

6

Agalsidase alfa and kidney dysfunction in Fabry disease.

West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. West M, et al. Among authors: schiffmann r. J Am Soc Nephrol. 2009 May;20(5):1132-9. doi: 10.1681/ASN.2008080870. Epub 2009 Apr 8. J Am Soc Nephrol. 2009. PMID: 19357250 Free PMC article.

7

Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.

Kampmann C, Linhart A, Devereux RB, Schiffmann R. Kampmann C, et al. Among authors: schiffmann r. Clin Ther. 2009 Sep;31(9):1966-76. doi: 10.1016/j.clinthera.2009.09.008. Clin Ther. 2009. PMID: 19843486

8

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, Pastores GM, Kampmann C, Ries M, Clarke JT. Schiffmann R, et al. J Pediatr. 2010 May;156(5):832-7, 837.e1. doi: 10.1016/j.jpeds.2009.11.007. Epub 2010 Jan 25. J Pediatr. 2010. PMID: 20097359 Clinical Trial.

9

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P. Schiffmann R, et al. Genet Med. 2013 Dec;15(12):983-9. doi: 10.1038/gim.2013.56. Epub 2013 May 16. Genet Med. 2013. PMID: 23680766 Free article. Clinical Trial.

10

Fabry Disease: A Disorder of Childhood Onset.

Schiffmann R, Ries M. Schiffmann R, et al. Pediatr Neurol. 2016 Nov;64:10-20. doi: 10.1016/j.pediatrneurol.2016.07.001. Epub 2016 Jul 29. Pediatr Neurol. 2016. PMID: 27555236 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

323 results

Search Page

Filters